An investment consortium led by Signet Healthcare Partners, Bionpharma and GMS Capital Partners has formed Pharma Nobis to acquire Fagron’s US contract manufacturing business. This business unit, operating from a manufacturing facility in Texarkana, TX, provides contract manufacturing and private label services for consumer healthcare companies and retailers in the United States. Fagron will retain a 20% stake in the company. Todd Daviau, co-founder and former president and CEO of CoreRx, a pharmaceutical contract development and manufacturing company, has been named CEO of Pharma Nobis.

“We are excited about the opportunity to invest in this company,” said James Gale, Managing Director of Signet Healthcare Partners. “Fagron has developed an exceptional company with a reputation as a cost-competitive manufacturer with a high service rating. We and our financial partners will seek to leverage this capacity and support the management team of Pharma Nobis in growing their business.

Alongside the acquisition, the company announced that James Gale, Theron Odlaug, Yezan Haddadin and Andrew Pulido would join its board of directors, alongside Mr Daviau. Dr. Odlaug is an experienced pharmaceutical executive and a Signet Venture partner. Yezan Haddadin is the CEO of GMS Capital Partners. Andrew Pulido is President of Fagron North America.

Previous

Everything you need to know about self-service business intelligence

Next

Self-Service Business Intelligence Software Market Size and Scope (2022-2030) by Major Key Players

Check Also